Cargando…
TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia
BACKGROUND: Cancer cells show increased glycolysis and take advantage of this metabolic pathway to generate ATP. The TP53-induced glycolysis and apoptosis regulator (TIGAR) inhibits aerobic glycolysis and protects tumor cells from intracellular reactive oxygen species (ROS)-associated apoptosis. How...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123356/ https://www.ncbi.nlm.nih.gov/pubmed/27884166 http://dx.doi.org/10.1186/s13045-016-0360-4 |
_version_ | 1782469719075323904 |
---|---|
author | Qian, Sixuan Li, Jianyong Hong, Ming Zhu, Yu Zhao, Huihui Xie, Yue Huang, Jiayu Lian, Yun Li, Yanru Wang, Shuai Mao, Jianping Chen, Yaoyu |
author_facet | Qian, Sixuan Li, Jianyong Hong, Ming Zhu, Yu Zhao, Huihui Xie, Yue Huang, Jiayu Lian, Yun Li, Yanru Wang, Shuai Mao, Jianping Chen, Yaoyu |
author_sort | Qian, Sixuan |
collection | PubMed |
description | BACKGROUND: Cancer cells show increased glycolysis and take advantage of this metabolic pathway to generate ATP. The TP53-induced glycolysis and apoptosis regulator (TIGAR) inhibits aerobic glycolysis and protects tumor cells from intracellular reactive oxygen species (ROS)-associated apoptosis. However, the function of TIGAR in glycolysis and survival of acute myeloid leukemia cells remains unclear. METHODS: We analyzed TIGAR expression in cytogenetically normal (CN-) AML patients and the correlations with clinical and biological parameters. In vivo and in vitro, we tested whether glycolysis may induce TIGAR expression and evaluated the combination effect of glycolysis inhibitor and TIGAR knockdown on human leukemia cell proliferation. RESULTS: High TIGAR expression was an independent predictor of poor survival and high incidence of relapse in adult patients with CN-AML. TIGAR also showed high expression in multiple human leukemia cell lines and knockdown of TIGAR activated glycolysis through PFKFB3 upregulation in human leukemia cells. Knockdown of TIGAR inhibited the proliferation of human leukemia cells and sensitized leukemia cells to glycolysis inhibitor both in vitro and in vivo. Furthermore, TIGAR knockdown in combination with glycolysis inhibitor 2-DG led leukemia cells to apoptosis. In addition, the p53 activator Nutlin-3α showed a significant combinational effect with TIGAR knockdown in leukemia cells. However, TIGAR expression and its anti-apoptotic effects were uncoupled from overexpression of exogenous p53 in leukemia cells. CONCLUSIONS: TIGAR might be a predictor of poor survival and high incidence of relapse in AML patients, and the combination of TIGAR inhibitors with anti-glycolytic agents may be novel therapies for the future clinical use in AML patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0360-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5123356 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-51233562016-12-06 TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia Qian, Sixuan Li, Jianyong Hong, Ming Zhu, Yu Zhao, Huihui Xie, Yue Huang, Jiayu Lian, Yun Li, Yanru Wang, Shuai Mao, Jianping Chen, Yaoyu J Hematol Oncol Research BACKGROUND: Cancer cells show increased glycolysis and take advantage of this metabolic pathway to generate ATP. The TP53-induced glycolysis and apoptosis regulator (TIGAR) inhibits aerobic glycolysis and protects tumor cells from intracellular reactive oxygen species (ROS)-associated apoptosis. However, the function of TIGAR in glycolysis and survival of acute myeloid leukemia cells remains unclear. METHODS: We analyzed TIGAR expression in cytogenetically normal (CN-) AML patients and the correlations with clinical and biological parameters. In vivo and in vitro, we tested whether glycolysis may induce TIGAR expression and evaluated the combination effect of glycolysis inhibitor and TIGAR knockdown on human leukemia cell proliferation. RESULTS: High TIGAR expression was an independent predictor of poor survival and high incidence of relapse in adult patients with CN-AML. TIGAR also showed high expression in multiple human leukemia cell lines and knockdown of TIGAR activated glycolysis through PFKFB3 upregulation in human leukemia cells. Knockdown of TIGAR inhibited the proliferation of human leukemia cells and sensitized leukemia cells to glycolysis inhibitor both in vitro and in vivo. Furthermore, TIGAR knockdown in combination with glycolysis inhibitor 2-DG led leukemia cells to apoptosis. In addition, the p53 activator Nutlin-3α showed a significant combinational effect with TIGAR knockdown in leukemia cells. However, TIGAR expression and its anti-apoptotic effects were uncoupled from overexpression of exogenous p53 in leukemia cells. CONCLUSIONS: TIGAR might be a predictor of poor survival and high incidence of relapse in AML patients, and the combination of TIGAR inhibitors with anti-glycolytic agents may be novel therapies for the future clinical use in AML patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13045-016-0360-4) contains supplementary material, which is available to authorized users. BioMed Central 2016-11-25 /pmc/articles/PMC5123356/ /pubmed/27884166 http://dx.doi.org/10.1186/s13045-016-0360-4 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Qian, Sixuan Li, Jianyong Hong, Ming Zhu, Yu Zhao, Huihui Xie, Yue Huang, Jiayu Lian, Yun Li, Yanru Wang, Shuai Mao, Jianping Chen, Yaoyu TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia |
title | TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia |
title_full | TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia |
title_fullStr | TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia |
title_full_unstemmed | TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia |
title_short | TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia |
title_sort | tigar cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5123356/ https://www.ncbi.nlm.nih.gov/pubmed/27884166 http://dx.doi.org/10.1186/s13045-016-0360-4 |
work_keys_str_mv | AT qiansixuan tigarcooperatedwithglycolysistoinhibittheapoptosisofleukemiacellsandassociatedwithpoorprognosisinpatientswithcytogeneticallynormalacutemyeloidleukemia AT lijianyong tigarcooperatedwithglycolysistoinhibittheapoptosisofleukemiacellsandassociatedwithpoorprognosisinpatientswithcytogeneticallynormalacutemyeloidleukemia AT hongming tigarcooperatedwithglycolysistoinhibittheapoptosisofleukemiacellsandassociatedwithpoorprognosisinpatientswithcytogeneticallynormalacutemyeloidleukemia AT zhuyu tigarcooperatedwithglycolysistoinhibittheapoptosisofleukemiacellsandassociatedwithpoorprognosisinpatientswithcytogeneticallynormalacutemyeloidleukemia AT zhaohuihui tigarcooperatedwithglycolysistoinhibittheapoptosisofleukemiacellsandassociatedwithpoorprognosisinpatientswithcytogeneticallynormalacutemyeloidleukemia AT xieyue tigarcooperatedwithglycolysistoinhibittheapoptosisofleukemiacellsandassociatedwithpoorprognosisinpatientswithcytogeneticallynormalacutemyeloidleukemia AT huangjiayu tigarcooperatedwithglycolysistoinhibittheapoptosisofleukemiacellsandassociatedwithpoorprognosisinpatientswithcytogeneticallynormalacutemyeloidleukemia AT lianyun tigarcooperatedwithglycolysistoinhibittheapoptosisofleukemiacellsandassociatedwithpoorprognosisinpatientswithcytogeneticallynormalacutemyeloidleukemia AT liyanru tigarcooperatedwithglycolysistoinhibittheapoptosisofleukemiacellsandassociatedwithpoorprognosisinpatientswithcytogeneticallynormalacutemyeloidleukemia AT wangshuai tigarcooperatedwithglycolysistoinhibittheapoptosisofleukemiacellsandassociatedwithpoorprognosisinpatientswithcytogeneticallynormalacutemyeloidleukemia AT maojianping tigarcooperatedwithglycolysistoinhibittheapoptosisofleukemiacellsandassociatedwithpoorprognosisinpatientswithcytogeneticallynormalacutemyeloidleukemia AT chenyaoyu tigarcooperatedwithglycolysistoinhibittheapoptosisofleukemiacellsandassociatedwithpoorprognosisinpatientswithcytogeneticallynormalacutemyeloidleukemia |